Earnings summaries and quarterly performance for OMI.
Executive leadership at OMI.
EP
Edward Pesicka
Detailed
President & Chief Executive Officer
CEO
AL
Andrew Long
Detailed
Executive Vice President, CEO, Products & Healthcare Services
HG
Heath Galloway
Detailed
Executive Vice President, General Counsel & Corporate Secretary
JS
Jennifer Stone
Detailed
Executive Vice President, Chief Human Resources Officer
JL
Jonathan Leon
Detailed
Executive Vice President & Chief Financial Officer
PB
Perry Bernocchi
Detailed
Executive Vice President, CEO, Patient Direct
Board of directors at OMI.
Research analysts who have asked questions during OMI earnings calls.
JS
John Stansel
JPMorgan Chase & Co.
4 questions for OMI
Also covers: ALHC, CAH, CNC +4 more
Kevin Caliendo
UBS
4 questions for OMI
Also covers: AHCO, ALGN, AMWL +15 more
Daniel Grosslight
Citigroup
3 questions for OMI
Also covers: AGL, CAH, COR +12 more
EC
Eric Coldwell
Robert W. Baird & Co.
3 questions for OMI
Also covers: AHCO, CAH, COR +9 more
Michael Cherny
Leerink Partners
3 questions for OMI
Also covers: ACCD, ALGN, CAH +18 more
Allen Lutz
Bank of America
2 questions for OMI
Also covers: ACCD, CAH, COR +14 more
AM
Ahmed Muhammad Rahat
Leerink Partners
1 question for OMI
Also covers: CERT, ICLR
AL
Alan Lutz
Bank of America Corporation
1 question for OMI
Also covers: HQY, HSIC
Jay Lewis
Robert W. Baird & Co. Incorporated
1 question for OMI
Also covers: PINC
SD
Stephanie Davis
Barclays
1 question for OMI
Also covers: ACCD, CAH, COR +20 more
Recent press releases and 8-K filings for OMI.
Owens & Minor Completes Sale of P&HS Business, Renames to Accendra Health
OMI
M&A
Management Change
- Owens & Minor, Inc. (OMI) completed the sale of its Products & Healthcare Services (P&HS) segment and the Owens & Minor brand to Platinum Equity on December 31, 2025.
- The transaction was valued at $375 million in cash, subject to customary adjustments, and included a 5% retained equity stake.
- The publicly traded parent company will be renamed Accendra Health, Inc., signifying its transformation into a pure play leader in the home-based care market, with a focus on its Apria and Byram brands.
- In connection with the sale, Andrew G. Long (Executive Vice President, Chief Executive Officer, Products & Healthcare Services) and Michael W. Lowry (Senior Vice President, Corporate Controller & Chief Accounting Officer) ceased their executive officer roles. Jonathan A. Leon (Executive Vice President & Chief Financial Officer) will assume the role of principal accounting officer.
Dec 31, 2025, 9:15 PM
Owens & Minor Completes Sale of P&HS Segment, Renames to Accendra Health
OMI
M&A
New Projects/Investments
- Owens & Minor, Inc. has completed the sale of its Products & Healthcare Services (P&HS) segment and the Owens & Minor brand to Platinum Equity.
- The publicly traded parent company has been renamed Accendra Health, Inc..
- The sale was completed for $375 million in cash, subject to customary adjustments, and included a 5% retained equity stake while preserving tax attributes in excess of $150 million.
- This transaction transforms the company into a pure play leader in the home-based care market, with Accendra Health focusing on its Apria and Byram brands.
Dec 31, 2025, 9:05 PM
Owens & Minor to Present at Investor Conferences and Provides Update on P&HS Sale
OMI
M&A
Guidance Update
New Projects/Investments
- Owens & Minor, Inc. management is scheduled to present at the Citi 2025 Global Healthcare Conference and the Bank of America Leveraged Finance Conference on December 2, 2025.
- The company's P&HS segment sale is on track to close in Q1 2026 or potentially by the end of 2025, positioning the company as a pure-play in the home-based care business.
- Post-sale, continuing operations are expected to generate more than $100 million in free cash flow per year after 2026, and the company anticipates repaying $280 million of current maturities related to the sale.
- For the third quarter of 2025, free cash flow from continuing operations was $28.317 million, with year-to-date free cash flow at $78.266 million.
Dec 2, 2025, 12:16 PM
Owens & Minor Announces Divestiture of PNHS Segment and Q3 2025 Results
OMI
M&A
Earnings
Guidance Update
- Owens & Minor announced a definitive agreement to sell its Products and Healthcare Services (PNHS) segment to Platinum Equity, with the transaction expected to close in Q1 2026. The company will retain an equity interest in the PNHS business.
- Following the divestiture, the public entity will be rebranded, and the company will become a pure-play business focused on home-based care through its Patient Direct segment.
- For Q3 2025, continuing operations reported revenue of $697 million, adjusted EBITDA of $92 million, and adjusted net income of $0.25 per share.
- The company affirmed its 2025 full-year guidance, expecting revenue between $2.76 billion and $2.82 billion, adjusted net income between $1.02 and $1.07 per share, and adjusted EBITDA between $376 million and $382 million. Full-year revenue is anticipated to be towards the bottom of the guidance range.
- The company expects a large customer loss in continuing operations in 2026, but notes it was not a margin-attractive or cash flow-positive contract.
Oct 30, 2025, 9:00 PM
Owens & Minor Announces Q3 2025 Results and PNHS Segment Sale
OMI
M&A
Earnings
Guidance Update
- Owens & Minor announced a definitive agreement to sell its Products and Healthcare Services (PNHS) segment to Platinum Equity, with the transaction expected to close in 2026. The public entity will be rebranded, focusing on its higher-margin Patient Direct segment.
- For Q3 2025, continuing operations (Patient Direct) reported revenue of $697 million and adjusted EBITDA of $92 million. Adjusted net income was $0.25 per share.
- The company affirmed its full-year 2025 guidance for continuing operations, projecting revenue between $2.76 billion and $2.82 billion, adjusted net income per share between $1.20 and $1.70, and adjusted EBITDA between $376 million and $382 million. Revenue is expected to be toward the bottom of the guidance range.
- Net debt was $2.1 billion as of September 30, 2025, with continuing operations generating $28 million in levered free cash flow during Q3 2025 and $78 million year-to-date.
Oct 30, 2025, 9:00 PM
Owens & Minor Provides Full Year 2025 Outlook
OMI
Guidance Update
Earnings
- Owens & Minor (OMI) has provided its Full Year 2025 outlook for continuing operations, projecting revenue between $2.76 billion and $2.82 billion.
- The company anticipates Adjusted EBITDA for Full Year 2025 to be in the range of $376 million to $382 million.
- Adjusted Net Income for Full Year 2025 is expected to be between $81 million and $85 million, with Adjusted EPS projected at $1.02 to $1.07.
Oct 30, 2025, 9:00 PM
Owens & Minor Reports Q3 2025 Financial Results and Announces Segment Sale
OMI
Earnings
M&A
Guidance Update
- Owens & Minor reported Q3 2025 revenue from continuing operations of $697.3 million.
- For Q3 2025, the company posted a GAAP loss from continuing operations of $(5.6) million (or $(0.07) per share) and Non-GAAP adjusted net income of $19.9 million (or $0.25 per share).
- The company announced a definitive agreement for the sale of its Products & Healthcare Services segment, which positions it as a pure-play home-based care business focused on its Patient Direct platform.
- Owens & Minor reaffirmed its 2025 financial guidance for continuing operations, projecting revenue between $2.76 billion and $2.82 billion, Adjusted EPS between $1.02 and $1.07, and Adjusted EBITDA between $376 million and $382 million.
Oct 30, 2025, 8:10 PM
Owens & Minor Reports Q3 2025 Results and Strategic Shift
OMI
Earnings
Guidance Update
M&A
- Owens & Minor reported revenue of $697.3 million from continuing operations for the third quarter ended September 30, 2025, compared to $686.8 million in the prior year period. The company posted a GAAP loss of $(0.07) per common share from continuing operations, while Adjusted net income from continuing operations per share was $0.25.
- The company has signed a definitive agreement for the sale of its Products & Healthcare Services segment, aiming to pivot its focus to become a pure-play Home-Based Care Business centered around its Patient Direct platform.
- For the full year 2025, Owens & Minor reaffirmed its financial guidance for continuing operations, projecting revenue between $2.76 billion and $2.82 billion, Adjusted EPS ranging from $1.02 to $1.07, and Adjusted EBITDA between $376 million and $382 million.
Oct 30, 2025, 8:05 PM
Owens & Minor Divests Healthcare Segment to Platinum Equity
OMI
M&A
New Projects/Investments
- Owens & Minor has entered into a definitive agreement to sell its Products & Healthcare Services segment to Platinum Equity for $375 million in cash, while retaining a 5% stake in the business.
- This strategic divestiture aims to transform Owens & Minor into a pure-play home-based care company, focusing on its Patient Direct platform.
- The company currently faces financial challenges, including negative profitability, liquidity constraints, and high leverage, reflected in an operating margin of 3.29% and a net margin of -13.78%.
- The divested Products & Healthcare Services segment was the larger revenue contributor compared to Patient Direct before the sale.
Oct 7, 2025, 9:51 PM
Owens & Minor Announces Definitive Agreement to Divest Products & Healthcare Services Segment
OMI
M&A
New Projects/Investments
- Owens & Minor, Inc. (OMI) has entered into a definitive agreement to sell its Products & Healthcare Services (P&HS) segment to Platinum Equity.
- The transaction includes a cash payment of $375 million to Owens & Minor at closing, subject to customary adjustments.
- Owens & Minor will retain a five (5) percent interest in the P&HS business and certain specified tax assets exceeding $150 million.
- This divestiture is intended to transform Owens & Minor into a pure-play market leader in the home-based care market.
- The transaction is subject to customary closing conditions and is expected to close near the end of the year.
Oct 7, 2025, 8:48 PM
Quarterly earnings call transcripts for OMI.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more